Treating post-traumatic uveitis by intravitreal injection of 0.7 mg dexamethasone implant (a clinical case)
https://doi.org/10.21516/2072-0076-2016-9-3-85-90
Abstract
Purpose: to assess the first results of intravitreal injection of an implant of dexamethasone 0.7mg for the treatment of post-traumatic uveitis and prevention of post-traumatic eyeball subatrophy. Material and Methods: patient А., 18 years old, was admitted to the hospital with the following diagnosis: a penetrating wound of the right eyeball, post-traumatic corneal scar, post-traumatic iridocyclitis, a posttraumatic swelling cataract, hemophthalmus, local peripheral retinal detachment. The left eye was undamaged. The right eye was given two intravitreal injections, with an interval of 4 months. Results. The follow-up of the patient showed an improvement after the first intravitreal injection of the implant manifested in reduced inflammatory response of the eye, IOP increased from 8 to 11 mm Hg, elongation of the anterioposterior axis of the eyeball from 16.02 mm to 21.63 mm, practically complete hemophthalmus resorption, a significant reduction of retinal edema. After the second intravitreal injection of the implant the positive changes developed: the visual acuity increased from 0.02 to 0.04, IOP increased from 11 to 14 mm Hg, the anterioposterior axis of the eyeball elongated from 21.63 mm to 21.67 mm, hemophthalmus resorbed completely and the retinal edema reduced. Conclusion. The clinical case demonstrates the effect of intravitreally injected implant of dexamethasone 0.7 mg in arresting the inflammatory process // Russian Ophthalmological Journal, 2016; 3: 85-90. doi: 10.21516/2072-0076-2016-9-3-85-90.
About the Authors
I. E. Ioshin
Hospital of the Executive Office of the President of the Russia Federation
Russian Federation
Russian Federation
A. S. Gavrilyuk
Hospital of the Executive Office of the President of the Russia Federation
Russian Federation
Russian Federation
A. V. Artamonova
Hospital of the Executive Office of the President of the Russia Federation
Russian Federation
Russian Federation
References
1. Архипова Л.Т., Гундорова Р.А., Xватова А.В. Эпидемиологические особенности и факторы риска симпатической офтальмии. Вестник офтальмологии. 1996; 4: 12-4.
2. Валеева Р.Г., Гришина B.C., Илуридзе С.Л. Клинико-иммунологические аспекты травматических увеитов, причины энуклеации. Вестник офтальмологии. 1997; 3: 38-41.
3. Гундорова Р.А., Малаев А.А., Южаков A.M. Травмы глаза. Москва: Медицина; 1986.
4. Кацнельсон Л.А., Танковский В.Э. Увеиты (клиника, лечение). Москва: 4-й филиал Воениздата, 1998.
5. Hunter R.S., Lobo A.M. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clinical Ophthalmology. 2011; 5: 1613-21.
6. Ashton P. Retinal Drug Delivery. In: Jaffe G.J., Ashton P., Pearson P.A., editors. Intraocular Drug Delivery. New York: Taylor Francis Group; 2006: 6-7.
7. Артемьева О.В., Самойлов А.Н., Жернаков С.В. Описание опыта клинического применения препарата Озурдекс. РМЖ. 2014: 17-20.
8. Parravano M., Oddone F., Boccassini B., et al. Exploring the morphological and functional retinal changes after Dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion. Ophthalmic research. 2014; 51(3): 153-60.
9. Burkholder B.M., Moradi A., Thorne J.E., Dunn J.P. The Dexamethasone intravitreal implant for noninfectious uveitis: practice patterns among uveitis specialists. Ocular Immunology and Inflammation. 2015;23(6): 444-53.
10. Nobre-Cardoso J., Champion E., Darugar A., et al. Treatment of Non-infectious Uveitic Macular Edema with the Intravitreal Dexamethasone Implant. Ocul Immunol Inflamm. 2016; 22 (Mar.): 1-8.
11. Лебедев Я.Б., Худяков А.Ю., Данилов О.В. Хирургическое лечение посттравматического циклодиализа, осложнённого гипотоническим синдромом. Современные технологии в офтальмологии. 2015; 2: 151.
12. Сухина И.В., Венгер Г.Е., Скринник А.А. Влияние импульсного электромагнитного поля в сочетании с атропином и кофеином в комплексном лечении посттравматической субатрофии глаза. Офтальмологический журнал. 1997: 2: 81-6.
13. Волков В.В. О перспективах борьбы с глазным травматизмом. Вестник офтальмологии. 1987; 5: 12-4.
14. Архипова Л.Т., Волик Е.И. Клинико-иммунологические факторы риска посттравматических увеитов. Иммунология. 1993; 5: 49-53.
15. Гундорова Р.А., Макаров П.В., Слепова О.С. и др. Клинико-иммунологические критерии активности воспалительной реакции и аутолимфокинотерапия при проникающих ранениях глаза. Вестник офтальмологии. 1996; 112(3): 19-21.
16. Аксенова Г.И., Гордеева В.В., Васильев И.Б., Мурашкина И.А. Системы доставки. Ч. 1. В кн.: Лекарственные формы с регулируемым высвобождением: учебное пособие. Иркутск: РПФ «Весь Иркутск»; 2012.
17. Amrite A.C., Kompella U.B. Nanoparticles for ocular drug delivery. Drugs and the pharmaceutical sciences. 2006; 159: 319.
18. Edelhauser H. F., Boatright J. H., Nickerson J. M., Third ARVO/Pfizer Research Institute Working Group, & Aguirre G.D. Drug Delivery to Posterior Intraocular Tissues: Third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. Invest Ophthalmol Vis Sci. 2008; 49(11): 4712-20.
19. Нестеров А.П., Басинский С.Н. Новый метод введения лекарственных препаратов в задний отдел субтенонового пространства. Вестник офтальмологии. 1991; 5: 49-51.
20. Fischer N., Narayanan R., Loewenstein A., Kuppermann B.D. Drug delivery to the posterior segment of the eye. European Journal of Ophthalmology. 2011; 21(6): 20-6.
21. Jong W.H., Borm P.J.A. Drug delivery and nanoparticles: applications and hazards. International Journal of Nanomedicine. 2008; 3(2): 133-49.
22. Edelhauser H.F., Rowe-Rendleman C.L., Robinson M.R., et al. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications. Invest. Ophthalmol. Vis. Sci. 2010; 51(11): 5403-20.
23. Patel A., Cholkar K., Agrahari V., Mitra A. Ocular drug delivery systems: an overview. World J Pharmacol. 2013; 2(2): 47-6.
24. Lee S.S., Hughes P., Ross A.D., Robinson M.R. Biodegradable implants for sustained drug release in the eye. Pharm. Res. 2010; 27(10): 2043-53.
25. Lowder C., Belfort R. Jr, Lightman S., et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011; 129(5): 545-53.
26. Haller J.A., Bandello F., Belfort R.Jr., et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011; 118(12): 2453-60.
27. Kuno N., Fujii S. Recent advances in ocular drug delivery systems. Polymers. 2011; 3(1): 193-221.
28. Bansal R., Bansal P., Kulkarni P., et al. Wandering Ozurdex(®) implant. J. Ophthalmic Inflamm. Infect. 2012; 2(1): 1-5.
Review
For citations:
Ioshin I.E., Gavrilyuk A.S., Artamonova A.V. Treating post-traumatic uveitis by intravitreal injection of 0.7 mg dexamethasone implant (a clinical case). Russian Ophthalmological Journal. 2016;9(3):85-90. (In Russ.) https://doi.org/10.21516/2072-0076-2016-9-3-85-90
Views:
1152
Email this article 